Allotera Therapeutics
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies
$35MSeries C
Role not disclosedActivity from announced rounds
Develops allogeneic, off-the-shelf CAR-T cell therapies for hematological malignancies